Moxetumomab pasudotox
As of the edition of 20 October 2026, Moxetumomab pasudotox is an antibody drug conjugate: marketed, first approved in 2018 (US); acts on CD22 and EEF2; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Antibody drug conjugate
- Brand name
- Lumoxiti
- First approved
- 13 September 2018 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- AstraZeneca
- Registered trials
- 10, 4 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Nervous system
US protection
US protection ends in 2030.
US protection ends in 2030, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by AstraZeneca. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Moxetumomab pasudotox.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 5 | 2 | 1 | 2 |
| Phase 2 | 3 | 1 | 0 | 2 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Acquired holder and Lead sponsor of trials | 2007 to now |
| Innate Pharma | Earlier holder | 2018 to now |